Harrow Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Harrow Inc 公司

Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Harrow Inc簡介



公司代碼HROW

公司名稱Harrow Inc

上市日期Feb 08, 2013

CEOMullery (Frank)

員工數量382

證券類型Ordinary Share

年結日Feb 08

公司地址1A Burton Hills Blvd

城市NASHVILLE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編37215

電話16157334731

網址https://www.harrow.com/

公司代碼HROW

上市日期Feb 08, 2013

CEOMullery (Frank)

Harrow Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Mark L. Baum, J.D.

Chairman of the Board, Chief Executive Officer

2.99M

+100006.00%

Mr. Andrew R. Boll

President, Chief Financial Officer, Company Secretary

811.18K

+33335.00%

Mr. Perry J. Sternberg

Lead Independent Director

--

Dr. Adrienne L. Graves, Ph.D.

Independent Director

--

Mrs. Lauren P. Silvernail

Independent Director

--

Mr. Amir Shojaei, Ph.D.

Chief Scientific Officer

--

Mr. Randall E. Pollard, CPA

Chief Accounting Officer

--

Mr. Frank Mullery

Chief Executive Officer of ImprimisRx

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Mark L. Baum, J.D.

Chairman of the Board, Chief Executive Officer

2.99M

+100006.00%

Mr. Andrew R. Boll

President, Chief Financial Officer, Company Secretary

811.18K

+33335.00%

Mr. Perry J. Sternberg

Lead Independent Director

--

Dr. Adrienne L. Graves, Ph.D.

Independent Director

--

Mrs. Lauren P. Silvernail

Independent Director

--

Mr. Amir Shojaei, Ph.D.

Chief Scientific Officer

--

收入明細

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Product Sales Net

71.50M

0.00%

Transfer of acquired product sales/profit

141.00K

0.00%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Product Sales Net

71.50M

0.00%

Transfer of acquired product sales/profit

141.00K

0.00%

股東統計

更新時間: 11月25日週二

持股股東

股東類型

持股股東

佔比

Opaleye Management Inc.

10.49%

Baum (Mark L)

8.06%

BlackRock Institutional Trust Company, N.A.

6.02%

The Vanguard Group, Inc.

5.17%

Private Capital Management

5.01%

其他

65.25%

持股股東

佔比

Opaleye Management Inc.

10.49%

Baum (Mark L)

8.06%

BlackRock Institutional Trust Company, N.A.

6.02%

The Vanguard Group, Inc.

5.17%

Private Capital Management

5.01%

其他

65.25%

股東類型

持股股東

佔比

Investment Advisor

21.53%

Investment Advisor/Hedge Fund

19.68%

Individual Investor

16.06%

Hedge Fund

14.36%

Research Firm

2.09%

Pension Fund

0.87%

Bank and Trust

0.37%

Insurance Company

0.03%

Private Equity

0.02%

其他

25.00%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

387

21.85M

59.00%

-2.41M

2025Q3

360

21.75M

58.77%

-3.27M

2025Q2

345

26.63M

72.57%

-2.99M

2025Q1

354

25.78M

70.87%

-4.22M

2024Q4

350

26.13M

73.38%

-4.49M

2024Q3

325

25.90M

72.95%

-2.80M

2024Q2

296

24.70M

70.19%

-6.36M

2024Q1

284

26.34M

74.95%

-7.20M

2023Q4

279

28.26M

80.94%

-4.94M

2023Q3

275

28.51M

81.73%

-152.59K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Opaleye Management Inc.

3.90M

10.54%

--

Sep 30, 2025

Baum (Mark L)

2.99M

8.06%

+100.01K

+3.47%

Dec 12, 2025

BlackRock Institutional Trust Company, N.A.

2.23M

6.02%

-24.19K

-1.07%

Sep 30, 2025

The Vanguard Group, Inc.

1.86M

5.03%

+131.00

+0.01%

Sep 30, 2025

Private Capital Management

1.86M

5.01%

-89.70K

-4.61%

Sep 30, 2025

Kaufman (Daniel)

1.68M

4.55%

-222.91K

-11.69%

Aug 12, 2024

Boll (Andrew R)

811.18K

2.19%

+33.34K

+4.29%

Dec 12, 2025

State Street Investment Management (US)

794.28K

2.14%

+21.18K

+2.74%

Sep 30, 2025

Geode Capital Management, L.L.C.

775.64K

2.09%

-35.16K

-4.34%

Sep 30, 2025

Royce Investment Partners

533.01K

1.44%

-20.68K

-3.73%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

State Street SPDR S&P Pharmaceuticals ETF

2.08%

Invesco Dorsey Wright Healthcare Momentum ETF

0.68%

First Trust Small Cap Growth AlphaDEX Fund

0.63%

iShares U.S. Pharmaceuticals ETF

0.46%

Invesco Dorsey Wright SmallCap Momentum ETF

0.37%

iShares Micro-Cap ETF

0.23%

First Trust Small Cap Core Alphadex Fund

0.2%

First Trust Multicap Growth Alphadex Fund

0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.08%

Avantis US Small Cap Equity ETF

0.08%

State Street SPDR S&P Pharmaceuticals ETF

佔比2.08%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比0.68%

First Trust Small Cap Growth AlphaDEX Fund

佔比0.63%

iShares U.S. Pharmaceuticals ETF

佔比0.46%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0.37%

iShares Micro-Cap ETF

佔比0.23%

First Trust Small Cap Core Alphadex Fund

佔比0.2%

First Trust Multicap Growth Alphadex Fund

佔比0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

佔比0.08%

Avantis US Small Cap Equity ETF

佔比0.08%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據